Bluebird Bio is a startup based in the United States, 2 tracked investors.
Bluebird Bio is a company founded in 1992 headquartered in the United States. Brouky records 2 investors associated with the company.
Bluebird Bio, now rebranded as Genetix Biotherapeutics, develops and commercializes genetic therapies based on gene-modified autologous blood stem cells to treat rare genetic diseases such as sickle cell disease, beta-thalassemia, and cerebral adrenoleukodystrophy.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.